What is the recommended work‑up and management for a squamous cell carcinoma of the right sinonasal fossa?

Management of Right Pterygopalatine Fossa Squamous Cell Carcinoma

For squamous cell carcinoma of the right pterygopalatine fossa (sinonasal region), proceed with surgical resection achieving clear margins followed by adjuvant radiotherapy, as this represents the standard of care for locally advanced sinonasal squamous cell carcinoma.

Initial Investigation

Imaging Work-up

• Obtain contrast-enhanced CT and MRI of the head and neck to define tumor extent, bone involvement, and soft tissue invasion 1
  • CT delineates bony destruction and skull base involvement
  • MRI is superior for soft tissue extent, perineural spread, and marrow involvement—critical for T-staging 1
  • The pterygopalatine fossa's proximity to skull base, orbits, and cranial nerves makes MRI essential for surgical planning

Metastatic Evaluation

• Perform CT chest with IV contrast for pulmonary metastasis screening 1
  • Sinonasal cancers present late with advanced local disease, warranting distant staging
  • Consider 18-FDG PET-CT for comprehensive nodal and distant metastasis assessment 2

Pathology

• Ensure expert pathological review for poorly differentiated or undifferentiated tumors 2
• Confirm squamous cell histology and differentiation grade, as this impacts prognosis

Treatment Algorithm

Primary Treatment Strategy

For Resectable Disease (Most Cases):

1. Surgical resection with clear margins is the cornerstone 2, 3

   • Achieve negative margins (tumor >5mm from margin for oral cavity; interpret cautiously for sinonasal sites) 4
   • Endoscopic approaches may be considered only if the tumor attachment site is fully visualizable and completely resectable 3
   • For pterygopalatine fossa involvement with anticipated poor visualization, craniofacial or transfacial approaches are appropriate 5

2. Follow with adjuvant radiotherapy (58-64 Gy) 4, 2

   • Use IMRT or VMAT techniques 4
   • Start within 6-7 weeks post-surgery 4

3. Add concurrent cisplatin (100 mg/m² on days 1,22,43) if high-risk features present: 4

   • R1 resection (microscopic positive margins)
   • Extracapsular nodal extension
   • Perineural infiltration
   • Lymphovascular invasion

   • 1 invaded lymph node

For T1 Lesions with Clear Margins:

• Surgery alone may be discussed in multidisciplinary tumor board 2
• This is the exception, not the rule

Neck Management

• Prophylactic radiotherapy to levels 1b, 2, and retropharyngeal nodes recommended for N0 patients 2
• Sinonasal SCC has lower but non-negligible nodal metastasis risk compared to other head and neck sites

Unresectable Disease

• Primary concurrent chemoradiotherapy (70 Gy with cisplatin 100 mg/m² every 3 weeks) 4
• Radiotherapy or chemotherapy alone are NOT recommended for curative intent 2

Special Consideration: Orbital Extension

• Discuss induction chemotherapy followed by concurrent chemoradiotherapy if orbital involvement precludes initial resection 2
• This remains controversial with expert disagreement

Critical Pitfalls to Avoid

1. Do not delay diagnosis: Sinonasal tumors commonly present late because symptoms (nasal obstruction, rhinorrhea, epistaxis) mimic benign sinusitis 1, 6

   • Unilateral symptoms unresponsive to medical therapy warrant immediate imaging and biopsy

2. Do not attempt endoscopic resection unless tumor attachment is fully visualizable 3

   • Positive margins significantly worsen disease-specific survival (p=0.0253)
   • The pterygopalatine fossa's deep location often requires open approaches

3. Do not omit adjuvant radiotherapy even with clear margins in locally advanced disease 2

   • Surgery alone is insufficient for most sinonasal SCC

4. Do not use radiotherapy or chemotherapy alone for operable tumors 2

   • This represents substandard care with inferior outcomes

Recurrent/Metastatic Disease

If disease recurs or presents as unresectable:

• For PD-L1 positive (CPS ≥1): Pembrolizumab monotherapy 4
• For PD-L1 negative or need for rapid tumor shrinkage: Pembrolizumab + platinum/5-FU 4
• After platinum failure: Nivolumab 4

Follow-up Protocol

Structured surveillance for minimum 5 years 2:

• Years 1-2: Every 3 months (4 times/year)
• Year 3: Every 4 months (3 times/year)
• Years 4-5: Every 6 months (2 times/year)

Each visit should include:

• Head and neck examination with endoscopy
• Imaging (CT or MRI) if clinical suspicion for recurrence
• FDG-PET useful for equivocal findings post-treatment 7

The evidence strongly supports aggressive surgical management followed by adjuvant therapy for sinonasal squamous cell carcinoma, as these tumors behave more aggressively than other head and neck sites and present at advanced stages 1, 8. Treatment must be delivered at high-volume centers with multidisciplinary teams 4.